Mammalian heparanase is an endo-β-glucuronidase associated with cell invasion in cancer metastasis, angiogenesis and inflammation. Heparanase cleaves heparan sulfate proteoglycans in the extracellular matrix and basement membrane, releasing heparin/heparan sulfate oligosaccharides of appreciable size. This in turn causes the release of growth factors, which accelerate tumor growth and metastasis. Heparanase has two glycosaminoglycanbinding domains; however, no three-dimensional structure information is available for human heparanase that can provide insights into how the two domains interact to degrade heparin fragments. We have constructed a new homology model of heparanase that takes into account the most recent structural and bioinformatics data available. Heparin analogs and glycosaminoglycan mimetics were computationally docked into the active site with energetically stable ring conformations and their interaction energies were compared. The resulting docked structures were used to propose a model for substrates and conformer selectivity based on the dimensions of the active site. The docking of substrates and inhibitors indicates the existence of a large binding site extending at least two saccharide units beyond the cleavage site (toward the nonreducing end) and at least three saccharides toward the reducing end (toward heparin-binding site 2). The docking of substrates suggests that heparanase recognizes the N-sulfated and O-sulfated glucosamines at subsite +1 and glucuronic acid at the cleavage site, whereas in the absence of 6-O-sulfation in glucosamine, glucuronic acid is docked at subsite +2. These findings will help us to focus on the rational design of heparanase-inhibiting molecules for anticancer drug development by targeting the two heparin/heparan sulfate recognition domains.
Introduction
Mammalian heparanase (Heparanase 1, HPSE or Hpa1) is an endo-β-D-glucuronidase that hydrolyzes/cleaves Heparan sulphate proteoglycans (HSPGs) at sites of injury or inflammation (Dempsey et al. 2000; Parish et al. 2001 ). This facilitates the structural alteration of the ECM and disrupts the basement membrane to allow for extravasation of inflammatory cells and liberation of growth factors and chemokines that induce proliferation and migration of endothelial cells and fibroblasts . Heparanase activity may therefore play a decisive role in disease-related processes such as cell invasion, angiogenesis and cancer metastasis (Nakajima et al. 1988; Elkin et al. 2001; Parish et al. 2001; Vlodavsky et al. 2008; Barash, Cohen-Kaplan, Dowek, et al. 2010) .
Human heparanase cDNA encodes the prepro-enzyme, which consists of 543 amino acid residues (65 kDa) with six N-glycosylation sites , five cysteine residues and a NH 2 -terminal signal peptide (Met1-Ala35).
Signal peptidase cleavage of the prepro-enzyme at Ala35 generates the latent ( pro-heparanase) 65 kDa heparanase. Proteolytic processing of the pro-enzyme removes a 6 kDa linker peptide (Ser110-Gln157), yielding an 8 kDa domain at the N-terminus (Gln36-Glu109) and a noncovalently linked 50 kDa catalytic domain with a lysine residue at the N-terminus (Lys158-Ile543) (Fairbanks et al. 1999) . These two polypeptides form a heterodimer, which is the mature and active form of heparanase (Fairbanks et al. 1999) . Heparanase acts with a β-retaining hydrolytic mechanism ( Figure 1 ) and belongs to family 79, clan A glycosyl hydrolases, containing an (α/β) 8 TIM-barrel fold Bairoch 1993, 1996; Hulett et al. 2000; Parish et al. 2001) . Site-directed mutagenesis and sequence alignments have indicated that catalysis involves two conserved acidic residues ( Figure 1 ): a proton donor at Glu225 and a nucleophile at Glu343 (Hulett et al. 2000) .
Three heparin/HS-binding sites have been identified: HBD-1 (domain 1, residues Lys158-Asn162), HBD-2 (domain 2, residues Gln270-Lys280) and HBD-3 (domain 3, residues Lys411-Arg432) (Levy-Adam et al. 2005) . We focused on HBD-1 and HBD-2 because of the presence of the GAG consensus motifs XBBXBX and XBBBXXBX (where B is the basic and X is the neutral and hydrophobic amino acid). The amino acids present in HBD-1 [KKFKNSTYSRSSVD(C); termed KKDC] directly interact with heparin/HS, resulting in the inhibition of both heparanase uptake and enzymatic activity, most likely due to competition of HS with the substrate. Notably, the KKDC sequence is in close proximity to catalytic residues Glu225 and Glu343 in the active site of the enzyme, thus making it an important target in the development of heparanase inhibitors. The above mode of action probably represents an HS-dependent nonenzymatic function of heparanase in its simplest form; however, evidence gathered in recent years indicates that heparanase also elicits HS-independent signaling ).
Heparanase cleaves both heparin and HS presumably at sites of low sulfation, releasing saccharide products of appreciable sizes (5-7 kDa) and biological potencies. Large efforts have been made to elucidate the substrate specificity and recognition mechanism of heparanase (Bame 2001) . Studies of the enzyme expressed in mouse and human melanoma cell lines have suggested that heparanase and heparin/ HS interacting protein recognize the same GAG sequence (Marchetti et al. 1997 ) and may cleave the chain either within or adjacent to the octasaccharide that contains the highly sulfated antithrombin III (AT)-binding sequence (Thunberg et al. 1982) . It has been observed that if the 2-O-sulfate group on the IdoA residue adjacent to the heparanase cleavage site is removed, then octasaccharide is no longer a substrate, suggesting that 2-O-sulfation on IdoA or GlcA is essential for recognition by heparanase, but not N-sulfation (Pikas et al. 1998) . Substrate specificity of recombinant heparanase was later investigated using tetra-and hexa-heparin/HS fragments (Okada et al. 2002) . It was found that (1) the minimum heparanase recognition site is a trisaccharide GlcN-GlcA-GlcN, wherein the GlcA is in the sulfated region; (2) the IdoA2S residue located two residues away from the target GlcA in the octasaccharide is not indispensable for the heparanase cleavage; and (3) heparanase cleaves the glycosidic linkage between GlcA and GlcNS, where GlcNS is either 6-O-sulfated or 3,6-O-disulfated. A recent study revealed that heparanase cleaves repeating disaccharides with certain sulfation types (Peterson and Liu 2010) . In addition to the cleavage of , heparanase cleaves the linkage between GlcA and GlcN with a GlcA2S residue in the close vicinity, but not IdoA2S. Interestingly, a Fig. 1 . Molecular representation of the mechanism of action of heparanase based on the retention mechanism of a β-glycosidase. Retaining glycosidases involve two carboxylates: one acts as a nucleophile and the other as an acid/base, with the distance between the nucleophile and acid/base being less than 5.5 Å. These enzymes operate through a two-step mechanism, with each step resulting in inversion, for a net retention of stereochemistry. During the first step, the nucleophile attacks the anomeric center, resulting in the formation of a glycosyl enzyme intermediate, with acidic assistance provided by the acidic carboxylate. In the second step, the now deprotonated acidic carboxylate acts as a base and assists a nucleophilic water to hydrolyze the glycosyl enzyme intermediate, giving the final hydrolyzed product. NS Gandhi et al. polysaccharide with repeating IdoA2S-GlcNS units is not a substrate of heparanase, but rather inhibits the activity of this enzyme (Peterson and Liu 2010) .
Different classes of molecules, including chemically modified natural products, small-molecule inhibitors and antibodies, have been described as heparanase inhibitors (Ferro et al. 2004; Miao et al. 2006; . A strong affinity inhibitor of heparanase is heparin (Nakajima et al. 1984) , wherein inhibition is best achieved by a heparin sequence containing 16 or more sugar units and having sulfate groups at both the N and O positions (Vlodavsky et al. 1994) . The HS mimetic PI-88 is a potent inhibitor of tumor growth and metastasis, and its anticancer activities are attributed to its inhibition of heparanase as well as its antagonism of the interactions of angiogenic growth factors with their receptors Ferro et al. 2007; Kudchadkar et al. 2008; Gandhi and Mancera 2010) . Currently, molecules are being developed that lack the anticoagulant activity typical of heparin but that are potent inhibitors of the enzymatic activity of heparanase (Irimura et al. 1986; Naggi 2005; Casu et al. 2008) . Examples of such molecules are glycol-split heparins (chemically modified heparins through the perodate oxidation of nonsulfated uronic acid residues) ). In the absence of the three-dimensional (3D) structure of heparanase, structure and/or ligand-based approaches have been implemented in the rational design of new high-affinity inhibitors (Ishida, Hirai, et al. 2004; Zhou et al. 2006; McKenzie 2007; Jalali-Heravi et al. 2008; Gozalbes et al. 2009 ).
This paper reports the molecular modeling study of various substrates and inhibitors such as glycol-split and PI-88 derivatives (Table I) . A deeper understanding of the nature of heparanase-heparin interactions will provide crucial information on the future design of novel molecules which might act as antiangiogenesis inhibitors to down-regulate the actions of heparanase.
Results and discussions

ConSeq analysis
A ConSeq analysis using the 543-residue-long human heparanase as the query sequence was carried out. The ConSeq results (Figure 2 ) reveal that 53 residues are predicted to be functionally important and 37 residues to have a structural role. ConSeq assigned conservation grades above average (color grades 6-9) in the catalytic domain, whereas the heparin-binding domains are not predicted to be conserved.
Among all heparanases, heparanase-2 (which is unable to degrade its substrate) possesses only 40% homology to heparanase-1 (McKenzie et al. 2000; Levy-Adam et al. 2010) . Two alternatively spliced variants of human heparanase-1 identified as having 485 and 169 amino acids are closely related to wild-type active enzyme heparanase-1. The 485 isoform results from the skipping of exon 5 and, as a consequence, lacks 174 base pairs encoding for 58 amino acids, including the active site proton donor (Glu225). Consequently, this alternatively spliced variant of heparanase-1 escapes proteolytic cleavage and is devoid of HS degradation activity (Nasser et al. 2007; Sato et al. 2008) . The 169 amino acid spliced form of human heparanase, termed T5, is a truncated, enzymatically inactive protein formed when 144 base pairs of intron 5 are joined with exon 4 (Barash, Cohen-Kaplan, Arvatz, et al. 2010) . The similarity tree ( Figure 3) shows that Spalax is situated on a branch separate from the mouse and rat heparanases, as reported previously (Nasser et al. 2005) , and rodents are situated in a cluster separate from other mammals (human and bovine). The Florida lancelet Branchiostoma floridae exhibits additional regions in the N-terminus although the core region is homologous to family 79 of glycosyl hydrolases. All the plant sequences are aligned on one side of the cladogram. These plant sequences comprise an additional conserved motif, e.g. "WWPpdKCdYgtC", where the lowercase indicates semiconserved residues when compared with other species.
Homology modeling (template selections, alignment preference, validation, H++) The secondary structure of the amino acid sequence predicted by the PSIPRED and NPSA servers is shown in Supplementary data, Figures S1 and S2, respectively. The secondary structure prediction reveals the presence of 25% helices, 12% strands and 63% coils at various positions in the protein structure, shown along with the level of confidence of the predictions. However, some discrepancies were observed between the predictions from PSIPRED and those from NPSA. PSIPRED predicted the presence of beta sheets in the region Lys161-Thr164 and Leu183-Gly188 and also predicted the presence of an α-helix in the region Tyr216-Leu222. On the other hand, PSIPRED, PHD and Predator predicted the presence of a strand in the region Glu378-Gln383, whereas DSC and MLRC overestimated the extent of the α-helix preceding this region. These differences in a secondary structure do not affect the modeling of HBD-1, HBD-2 and the catalytic residues.
Analyses of the heparanase sequence by various 3D protein structure modeling web servers, such as Phyre (Kelley and Sternberg 2009) , HHPred (Soding et al. 2005) , I-TASSER (Zhang 2008 (Zhang , 2009 Roy et al. 2010) and Fugue (Shi et al. 2001) , resulted in structural template matches with a sequence identity <17%. The templates, along with their sequence identity from HHPred, are reported in Table II . All the templates retain enzymes with very similar (β/α) 8 folds and are superimposable over the main chain atoms. However, most of the enzymes differ in their respective catalytic sites, depending on the ability of a glycoside hydrolase to cleave a substrate at the end (exo-acting) or within the middle of a chain (endo-acting). The active sites of exo-acting glycosyl hydrolases are pocket-shaped, whereas endo-acting enzymes generally have an open, extended substrate-binding cleft that can interact at random positions along the saccharide chains (Davies and Henrissat 1995) . Hence, the selection of the templates on the basis of the type (endo-or exo-acting) of glycoside hydrolases is critical for the rational design of inhibitors of heparanase.
The top hit templates (PDB codes 2C7F, 1QW9, 2VRQ, etc.) (Hovel et al. 2003; Taylor et al. 2006; Paes et al. 2008) belong to the exo-acting arabinofuranosidase family 51, Molecular modeling of the interactions of heparanase and oligosaccharides which preferentially hydrolyzes the α(1 → 3) linkage of arabinose-containing branched substrates and releases arabinofuranosyl moieties. The crystal structures of branched substrate complexes with arabinofuranosidase reveal the presence of extended substrate-binding sites that appear to be induced by substrate binding. Hence, caution should be exercised while using members of this family as templates for the homology modeling of heparanase. The homology modeling of heparanase previously reported (Ishida, Hirai, et al. 2004; Zhou et al. 2006 ) was carried out using the structure of the family 10 1,4,β-xylanase (PDB code 1BG4) (Schmidt et al. 1998 ) which has a shallow active site. Similar to heparanase, xylanase (PDB code 1BG4) is β-retaining and endo-acting; however, the two enzymes differ in their substrates. Aldopentose serves as a substrate for xylanase, whereas hexapyranose as a substrate for heparanase. A current PSI-BLAST search shows β-D-xylosidase (PDB codes 1UHV, 2BS9, etc.) (Yang et al. 2004; Czjzek et al. 2005) to be a closer match, however, this enzyme hydrolyzes the substrate at the end. Furthermore, Modbase considers family 30 human β-glucoside (PDB code 1OGS) (Dvir et al. 2003) as the best template but is only able to provide a model of heparanase in the amino acid range 187-466 due to the lack of structural folds in other regions. On the other hand, members of family ΔHexA, unsaturated uronic acid; GlcA, β-D-glucuronic acid; GlcN, α-D-glucosamine; 2S, 2-O-sulfate; 6S, 6-O-sulfate; NS, 2-N-sulfate; AGA*IA, GlcNAc6S-GlcA-GlcNS,3,6S-IdoA2S-GlcNS6S; gs, glycol-split; MHS, maltohexaose sulfate; PI-88, phosphomannopentaose polysulfate, AGA*IA taken from X-ray structure (PDB:2GD4).
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44 (clan not classified), which have composite domains of the glycosyl hydrolase families 5, 30, 39 and 51, are endo-acting and act on the substrates containing (β-D-glucopyranosyl-(1 → 4)) n -β-D-glucose motifs (where n = 1-5). Besides family 79, β-glucuronidase is classified under the glycosyl hydrolase family 2, which also catalyzes the hydrolysis of β-D-glucuronic acid residues from the nonreducing end of HS. However, human β-glucuronidases in families 2 and 79 lack appreciable sequence and structural similarity (PDB codes 1BHG and 3HN3) (Jain et al. 1996) . In particular, all threading programs fail to correctly align the HBD-1. Heparanase is endo-acting and cleaves pyranose substrates with a 1,4-β linkage. Consequently, endoglucanases (PDB codes 3IK2 and 2E4T) (Kitago et al. 2007; Warner et al. 2010) were selected as the Fig. 2 . ConSeq predictions on human heparanase (SWISS-PROT: Q9Y251), using nonredundant homologs obtained from the CLEAN_UNIPROT (filtered UNIPROT database in Consurf ). The sequence of the query protein is displayed with the evolutionary rates color coded in each site (see legend). The residues of the query sequence are numbered starting from 1. The residues in the catalytic sites are predicted to be structurally and functionally important, "s" and "f", respectively, whereas the heparin-binding domains are not conserved but exposed to the surface.
Molecular modeling of the interactions of heparanase and oligosaccharides most appropriate templates to model the heparanase sequence. The sequence alignment as obtained using HHPred is shown in Figure 4 . Generally speaking, the alignment in the catalytic regions is consistent with the secondary structure prediction ( Figure 4) ; however, sequence-structure alignment with the majority of the templates mentioned in Table II using any of the 3D recognition method fails to assign conserved secondary structures in the region from Asp125 to Gln157. As a consequence, secondary structure restraints were applied while producing a homology model with MODELLER. As a further evaluation of the homology-modeled structures of heparanase (residues 157-543), the model with the lowest probability density function (PDF) energy was selected from a set of 20 models and its backbone ψ and w dihedral angles were analyzed using the Ramachandran plot. In this model, 86.6, 11.0 and 1.8% of the residues are located within the most favorable, additionally allowed and generously allowed regions, respectively, with only two residues being found in the disallowed region ( Figure 5 ). The C-terminal residues were the ones in the generously allowed and disallowed regions. The heparin-binding sites and the catalytic residues were found within the most favorable region of the Ramachandran plot. The homology model was also analyzed using VERIFY 3D, which assessed and confirmed the quality of the predicted structure of heparanase with acceptable 3D-1D average scores. The scores were added and plotted for residues 157-543 ( Figure 6 ). Residues at the C-terminus with values ≤0.1 are predicted with less accuracy and are likely to have less stable conformations. It can be seen that most of the residues, including the heparin- Overall, the alignment is consistent with the consensus secondary structure prediction.
Molecular modeling of the interactions of heparanase and oligosaccharides
binding domains and catalytic sites, have values in the range 0.2-0.78. These assessments suggest that the modeled structure is of reasonable quality, given the low sequence homology between the templates and the target, as shown in Figure 4 . Analysis of the molecular surface and electrostatic potential of modeled heparanase reveals the presence of electropositive regions (due to positively charged residues) in HBD-1 and HBD-2 ( Figure 7A ). The distance between the centroid of residues in HBD-1 and HBD-2 is 26 Å, which is important for the binding of heparin oligosaccharides larger than a hexasaccharide. The crystal structure of the Cel44A structure bound with a substrate (cellooctaose) from Clostridium thermocellum (PDB code: 2EQD) was used to compare residues with the model of heparanase. This structure was chosen in order to get a general impression of how heparanase might require an oligosaccharide to bridge the heparin-binding domains and cleave an octasaccharide ( Figure 7B ) that contains the highly sulfated AT-binding sequence. Table III shows a list of the residue differences in the catalytic and heparinbinding domains. The pyranose rings in cellooctaose are surrounded primarily by tryptophan residues, whereas other residues dominate this site in heparanase (Table III) . Superimposition of a complex of cellulase with its substrate shows that the acidic groups of Glu225 and Glu343 are very close to the cleavage point between the β-1,4 glucose units; however, there are steric clashes observed with cellooctaose and HBD-1. HBD-1 has a coiled-coil structure at the terminal and may undergo further conformational changes during molecular dynamics (MD) simulations. These steric clashes with HBD-1 can be avoided by replacing the β-1,4 linkage with an α-linkage in the ligand.
PSFloger (Protein Structure and Function Loger) (Mukherjee et al. 2010 ) was used to identify the structural and functional analogs of heparanase. This web server takes the ligand(s) in analog structures and transfers them to the model structure for comparison of the local structure and sequence similarity in the binding site. It also annotates the function of the target protein (ligand-binding sites, It can be seen that 86.6, 11.0 and 1.8% of the residues are located within the most favorable, additionally allowed and generously allowed regions of the Ramachandran plot, respectively, with only two residues found in the disallowed region. Given the low sequence identity and abundant presence of coils, the model can be described as being of good quality.
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Gene-Ontology terms, enzyme classifications) by global and local matches of the structure with known protein function libraries. Supplementary data, Table S2 shows the binding site residues being identified on the heparanase model. Members of family 30 glycoside hydrolase, which is responsible for hydrolyzing the β-glucoside from the glycolipid glucosylceramide, show high resemblance in the catalytic binding site to heparanase (PDB codes 2VT0 and 2V3F). Although these analog structures are cocrystallized with sulfate ions, none map to the heparin-binding domains in the heparanase model upon superimposition. In fact, three sulfate ions map to the C-terminal β-barrel domain. These results suggest that the heparin-binding domains (in particular, HBD-1) are highly variable compared with other members of clan A, which might explain variations in specificity of different binding substrates.
For catalysis to take place, the proton donor must be protonated, and the nucleophilic attack and the stabilization of the intermediate are to be mediated by a protein residue with a free lone pair or a negative charge (nucleophile). Consequently, the pK a of the proton donor (Glu225) should be at least 5.0 and the pK a of the catalytic nucleophile (Glu343) should be at least 1.5 units lower than that of the proton donor McCammon 2003a, 2003b) . Subsequent benchmarking of the two approaches (H++ and PROPKA) to predict pK a values with the set of templates listed in Table II shows the PROPKA approach to be superior, with pK a values of titrable groups in the active site matching those mentioned in the literature. PROPKA gave equally good predictions with a set of xylanases reported previously Kongsted et al. 2007 ). In all the glycosyl hydrolases, including the heparanase model reported here, the pK a of the proton donor (Glu225) was higher than 5.0 and hence it was protonated, while the pK a of the catalytic nucleophile (Glu343) was lower than the pK a value of the proton donor. Supplementary data, Table S3 lists residues chosen based on initial pK a predictions using PROPKA with the energy-minimized homology model of heparanase.
Molecular dynamics simulations
The homology model of heparanase was further refined using MD simulations, which also allowed an assessment of conformational changes in the HDB-1. After energy minimization and equilibration, a 1.0 ns production run was performed and trajectory data were collected for analyses. The timedependent profile of the potential energy was plotted (figure not shown) wherein the potential energy decreases gradually 
Molecular modeling of the interactions of heparanase and oligosaccharides from the start and then stabilizes after 500 ps. The RMSD of backbone atoms (C, Cα and N) between the initial modeled structure and the final structure at the end of the MD simulation was 1.5 Å. The Lys residues in the 158-160 range adopt a 3 10 -helical conformation after 800 ps, which matches the secondary structure prediction of the NPSA server (see above). Even after the MD refinement of heparanase model alone, steric clashes are still observed upon superimposition of the cellooctaose substrate discussed above. The persistence of this steric hindrance may cause a considerable deterioration in the accuracy of ligand-protein docking approaches. While a longer simulation may be necessary to sample the conformational change in the modeled enzyme, such an extended simulation without restraints might result in distortions of the catalytic binding site and changes to the rotameric preferences of the nucleophile and proton donor residues located in the loop regions. Such problems may be rectified by local refinement of ligand-binding regions (in this case, the catalytic and heparin-binding regions) in protein models using remotely related templates identified by threading or using induced-fit docking.
Binding site analysis and molecular docking To dock substrates into the modeled structure of heparanase, FINDSITE was used to identify the putative ligand-binding pose and conserved anchor region geometries based on binding-site similarity across groups of weakly homologous template structures identified by threading. The results of FINDSITE are provided as data files in the Supporting Information.
1 The top-ranked binding sites included the catalytic residues and heparin-binding domains HBD-1 and HBD-2. In most of the cases, the ligands were hexapyranoses with β-(1,4)-linkages and belong to the antiprotonation class of retaining enzymes. Superimposition of heparanase with the holo-enzymes indicates that family 79 enzymes such as heparanase are antiprotonators. In addition, the two catalytic residues are separated by a distance of 4.87 Å, which is consistent with hydrolysis occurring via a retention mechanism.
The results of FINDSITE also suggest the presence of β-D-glucose rings at subsite −1 [cleavage occurs between subsites −1 and +1, with nonreducing and reducing ends being labelled with −n and +n signs, respectively (Davies et al. 1997) ]. To start docking, the last nonreducing ring of each substrate described in Table I was superimposed with the average position of the pyranosyl rings at the cleavage site (near subsite −1) of the substrates derived from the results of FINDSITE.
Apart from the hexapyranose rings and furanose rings, core structures containing ring systems such as piperidin, 1 The file findsitepocket.rtf (cwr095supp3.rtf ) contains information on binding pockets identified by the spatial clustering of template-bound ligands aligned to the target crystal structure and ranked by the number of binding ligands. The file findsitefunction.rtf (cwr096supp2.rtf ) contains function annotation (GO ontology) of heparanase using the templates selected by structure similarity. The file findsitealignments.rtf (cwr095supp1.rtf) has template structures that have been selected from the template library by structure alignments to the native heparanase model.
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morpholin, pyridine and indole rings were mapped near the cleavage site, according to the FINDSITE analysis. Ligands such as cellooligosaccharides and their sulfur (thio)-substituted glycosidic linkages, and GlcNAc covered the rest of the subsites from −4 to +4. Thio-linked oligosaccharides, wherein at least one glycosidic bond oxygen atom is replaced with a sulfur atom [PDB codes 1E5J (Fort et al. 2001) , 1H5V , 2O9R (Isorna et al. 2007) and 3CUI], are well-established substrate mimics and competitive inhibitors of glycosidases (Driguez 2001) , and one such potential inhibitor of heparanase, the S-linked trisaccharide, is already known (Cao and Yu 2005) .
The mapping of molecules into the various subsites of heparanase might help us to establish whether such molecules are good substrates of heparanase and, if so, whether the introduction of side chain substituents such as sulfone or phosphate groups on core structures and/or changes in the substituents at the glycosidic linkage (β vs. α) can be employed for searching carbohydrate-based inhibitors of GAG-heparanase interactions. For example, one of the ligands bridging HBD-1 and HBD-2 [site 18 of FINDSITE analyses, PDB code 3K8L (Koropatkin and Smith 2010) ] is maltohexaose/maltoheptaose (α-1,4-linked glucose), whereas its polysulfated analog 11 (MHS; maltohexaose sulfate with at least 3 sulfate groups per internal sugar and up to four sulfates in the terminal sugar residues) is already known to be a good inhibitor of heparanase (IC 50 = 5 μg/mL compared with heparin with IC50 = 2 μg/mL) . MHS was docked onto the heparanase catalytic binding site and heparin-binding domains and its various interactions are shown in Figure 8 . Residues Lys159 and Lys161 of HBD-1 and Arg272 of HBD-2 make electrostatic interactions with the sulfates, whereas Gln270 is involved in hydrogen bonding with one of the sulfates of MHS. The majority of docked poses showed similar binding with Tyr298 through hydrogen bonding at a distance of 3.0 Å. Several interactions are made with the loop, which consists of residues Asn227-Leu230. Phe229 and Leu230 are involved in hydrophobic interactions, the side chain of Asn227 makes hydrogen bonds with the sulfates, and the side chain and backbone of Lys231 make electrostatic interactions and hydrogen bonds with the side chains of MHS. In general, maltohexaose adopts a "U-shaped kinked structure", however, superimposition of the docked MHS and maltohexaose (PDB: 3K8L) indicates the occurrence of a different binding mode. This binding mode of MHS blocks the catalytic site as well as bridges both HBD-1 and HBD-2. This validates our hypothesis that the addition of sulfated substituents to the core structure can be used in the rational design of new GAG mimetics.
Manual docking of compound 1 has been reported previously (Ishida, Hirai, et al. 2004 ). The disaccharide unit in compound 1 in the absence of sulfation is known to be a resistant to catalytic digestion (Okada et al. 2002; Peterson and Liu 2010) . The docking simulations reported here revealed that cluster 1, with the majority of the binding poses, has GlcA in subsite +1, while GlcNAc is docked near the cleavage site ( Figure 9A ), whereas an inverse binding mode was reported in a previous study (Ishida, Hirai, et al. 2004) . As a consequence, the distance between the anomeric carbon of GlcA and the side chain of nucleophile Glu343 is greater than 6.0 Å, which might render compounds resistant to catalytic digestion. The hydroxyl groups of GlcNAc form hydrogen bonds with the side chains of Tyr298 and Lys231. The second largest cluster with 14 poses has GlcA placed in subsite −1 and the glycosidic linkage is located further away from the catalytic residues.
Similarly, 6-O-sulfo heparosan (2) and N-sulfo heparosan (3) are resistant to cleavage by heparanase (Pikas et al. 1998; Peterson and Liu 2010) . Clustering of the docked poses of compound 2 indicates that the catalytic residues are at a distance of 5.8 Å from the glycosidic linkage and hence the substrates cannot be cleaved. The GlcA residue is not exactly placed at the subsite −1. The 6-O-sulfate of compound 2 is involved in hydrogen bonding with Gln270, whereas the carboxylic acid of GlcA interacts with the charged side chain of Lys159 and with Tyr298. The adjacent hydroxyl groups (at C2 and C4) of GlcA are within the hydrogen bonding distance from Glu343 and Glu225. The average binding energies for compound 3 in most of the clusters were positive. The Fig. 9 . Conformations of docked substrates (compounds 1 and 5) and inhibitor (compound 7) in the heparanase-binding site. Hydrogens are not shown for clarity. (A) Docking of compound 1 shows that the distance between the anomeric carbon of GlcA and the side chain of nucleophile Glu343 is greater than 6.0 Å, rendering compound 1 resistant to catalytic digestion. The hydroxyl groups of GlcNAc form hydrogen bonds with the side chains of Tyr298 and Lys231. (B) The top-ranked pose of compound 5 reveals that the distance between the oxygen of the glycosidic linkage and the protonated Glu225 is 3.8 Å and that the distance between the anomeric carbon and Glu343 is 3.9 Å. This indicates that heparanase can cleave this substrate. (C) Docking of inhibitor 7 shows that IdoA2S in the skew-boat conformation fits in the cleavage site with GlcNS being placed at subsite +1; however, the distance between the glycosidic bond oxygen and Glu225 was measured to be >5 Å.
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GlcA residue is docked in subsite +2 in the vicinity of Gln270, while the N-sulfate makes electrostatic interactions and a hydrogen bond with Lys159 and Tyr298, respectively. The NH of GlcNS forms a hydrogen bond with Glu343.
Both N-and O-sulfations (6-O-sulfation or 3-O-sulfation) are required for cleavage by heparanase, as shown by experimental data for substrates 4 and 5. In the top-ranked pose of compound 4, the distance between the oxygen of the glycosidic linkage and the protonated Glu225 is 4.0 Å and that between the anomeric carbon and Glu343 is 4.2 Å. The N-sulfate of compound 4 interacts with the charged side chain of Lys231, while the O-sulfate interacts with the side chain of Gln270. The hydroxyl group at position 3 of GlcA of compound 4 is within hydrogen bonding distance of the side chain of Tyr296. Docking of compound 5 revealed the formation of a hydrogen bond between the carboxylic acid of GlcA and Tyr298, whereas the 6-O-sulfate and the pyranose oxygen form hydrogen bonds with Gln270. In top-ranked pose of compound 5, the distance between the oxygen of the glycosidic linkage and the protonated Glu225 is 3.8 Å and that between the anomeric carbon and Glu343 is 3.9 Å ( Figure 9B ). The most populated clusters upon docking compounds 4 and 5 show that the GlcA residue is in the plane of Glu225 and that the C1-O5 bond is "anti" to the catalytic residue. In the case of substituted GlcA (compound 6), the docking simulations indicate that GlcA2S is located toward site 2, whereas GlcNS is between the cleavage site and subsite −1. These findings are consistent with experimental data showing that heparanase does not cleave the linkage of GlcA2S-GlcNS directly, but rather cleaves the linkage of the neighboring GlcA-GlcNS (Peterson and Liu 2010) . Electrostatic interactions between the 2-O-sulfate of GlcA2S of substrate 6 and the side chain of Lys159 and between the N-sulfate of GlcNS and His296 are also observed. The hydrophobic Phe160 is in close proximity to the glycosidic linkage of substrate 6. The hydroxyl groups in GlcNS form hydrogen bonds with the side chain of Glu225. Hydrogen bonds are also observed between the amide of GlcNS and Gly269 and between the sulfate and backbone of Tyr298.
Sulfated iduronic acid (IdoA2S) adopts either the 1 C 4 chair conformation or the skew-boat 2 S 0 conformation (Mulloy et al. 1993) . Therefore, docking simulations of compound 7 were performed with IdoA2S using both conformations. IdoA2S in the skew-boat conformation was found to fit at the cleavage site with GlcNS being placed at subsite +1; however, the distance between the glycosidic bond oxygen and Glu225 was measured to be >5 Å. In the chair conformation, IdoA2S was found to sit at subsite +1. The 2-O-sulfate of IdoA2S interacts through electrostatic interactions and hydrogen bonds with the side chains of Arg272 and Gln270, respectively. The amide group makes a hydrogen bond with the side chain of Tyr298. An electrostatic interaction between Lys159 and the N-sulfate group is observed, whereas the hydroxyl groups of GlcNS form hydrogen bonds with Glu343 and Lys231. The computed free energy of interaction of this disaccharide is lower with the chair conformation of IdoA2S compared with that of the boat conformation (Table IV) . The computed free energies of interaction and the cluster analyses show that the chair conformation of IdoA2S might be the preferred form adopted in the heparanase-binding site. The α-linkage containing disaccharide is further away from catalytic residues and hence might be resistant to cleavage ( Figure 9C) ; however, the docking simulations performed are not able to explain the mechanism of action of compound 7 as an inhibitor on the basis of the interactions of sulfates alone. The sequence preceding and following this disaccharide unit might also influence its behavior as an inhibitor or substrate. However, taken together, the results from FINDSITE discussed above and the docking of maltohexaose and compound 7 suggest that it is possible that the conformational change in the linkage (α in the IdoA2S disaccharide vs. β in the GlcA disaccharide) might be one of the factors that determine the behavior of these molecules as inhibitors.
The docking simulations of substrates listed in Table IV suggest that heparanase recognizes the N-and O-sulfated glucosamine at subsite +1 and interacts with GlcA at the cleavage site (near to subsite −1). In the absence of 6-O-sulfation in glucosamine, GlcA is found at subsite +2, which is in agreement with experiments (Peterson and Liu 2010) .
The top-ranked cluster of 8 shows that GlcA is docked at the cleavage site, that is, the distance between oxygen of the glycosidic linkage and protonated Glu225 is 3.4 Å and that between anomeric carbon and Glu343 is 4.36 Å. As for free energy of binding, heparanase showed the highest activity against the trisaccharide (Table IV) . The 6-O-sulfate and N-sulfate of GlcNS6S at subsite +1 form hydrogen bond with the backbone of Tyr298 and with a side chain of Gln270, respectively, at a distance of 3.5 Å. No ionic interactions with the COO − group of GlcA were observed. The N-sulfate of GlcNS6S at subsite +1 forms hydrogen bond with the side chain of Tyr298 and the amide forms hydrogen bond with the backbone oxygen of Gly389. Although 6-O-sulfate at the nonreducing end is in close proximity of HBD-1, we did not observe any ionic interactions at 3.5 Å. Docking simulations of compound 8 reveal that, while the trisaccharide is essential for recognition by heparanase, the binding site is large enough to accommodate another sugar residue such as ΔHexUA at subsite −2 or +2. Consequently, a tetrasaccharide containing the above sequence would be an ideal substrate.
The optimal length of a heparin chain required to bridge HBD-1 and HBD-2 for the effective inhibition is known to be an octadecasaccharide Vlodavsky, Ilan, Nadir, et al. 2007 ), whereas heparin tetrasaccharides and hexasaccharides as well as N-acetylated heparins (N-acetylation higher than 50%) are poor inhibitors of heparanase (Bar-Ner et al. 1987; Naggi et al. 2005) . Nonetheless, the pentasaccharide AGA*IA (compound 9), corresponding to the heparin/HS sequence that interacts with the active site in AT, is susceptible to cleavage by heparanase (Bisio et al. 2007 ). Two-dimensional nuclear magnetic resonance (2D NMR) determinations revealed the presence of a strong interaction of this pentasaccharide with HBD-1 (Levy- Adam et al. 2005) . The docking simulations reported here revealed that GlcA is positioned at subsite −1 and the 6-O sulfate of GlcNS6S preceding GlcA make electrostatic interactions with Lys158 and Lys161, whereas the N-sulfate of GlcNS6S interacts with the side chain of Lys231. The 3-O-sulfate of GlcNS3S6S is not directly involved in electrostatic NS Gandhi et al. , IdoA; , GIcA; , N-acetylated glucosamine; , N-sulfated glucosamine. The architecture of the substrate/inhibitor-binding sites (subsites) adjacent to the cleavage site is shown. The subsites are labelled with negative numbers for subsites to the right (nonreducing end) and positive numbers to the left (reducing end) of the catalytic site.
Molecular modeling of the interactions of heparanase and oligosaccharides interactions, whereas the 6-O-sulfate makes a hydrogen bond with Tyr298. The 6-O-sulfate of GlcNS6S at the reducing end makes electrostatic interactions with the side chains of Arg272 and Gln270 in HBD-2. In some of the predicted binding modes, the carboxylic acid of GlcA makes an electrostatic interaction with Lys161. The catalytic residues were found to be at a distance of 4.5 Å from the anomeric carbon and glycosidic linkage and hence make the oligosaccharide susceptible to cleavage. The 2-O-sulfate of IdoA2S was not involved in any interaction, which explains the experimental observation that the desulfation of the IdoA residue has very little effect on the inhibitory activity of heparin . The sequence AGA*IA (compound 9) has anticoagulant activity. Consequently, heparanase inhibitors need to be nonanticoagulant heparin mimics, with antimetastatic and antiangiogenic activity and without favoring the release and activation of growth factors. Examples of such molecules are acetylated heparins in their glycol-split forms (which involves splitting of C2-C3 bonds of nonsulfated uronic acid). The N-acetylated, glycol-split heparin such as 100 NA,RO.H inhibits heparanase activity at nanomolar concentrations and has no anticoagulant activity . In this study, a glycol-split was introduced in the AGA*IA sequence (henceforth referred to as gs-AGA*IA). In principle, the sugar units A*IA of compound 10 should occupy similar positions in the catalytic binding site as the natural pentasaccharide. Docking simulations revealed the presence of conformations that can be grouped into two clusters and are different from that of AGA*IA bound to heparanase. The difference in both ligand conformations lies in the interaction of the terminal end residue. The N-sulfate in one conformation interacts with HDB-1, whereas in the other it interacts with HBD-2. Hence, this suggests that at least one N-sulfate group is required to inhibit heparanase activity as effectively as the corresponding N-acetylated glycol-split derivatives ). Furthermore, in both clusters, the 2-O-sulfates of IdoA2S form hydrogen bonds with the side chain of Ser228 and with the backbones of Phe229 and Ala230. The glycol-split GlcA modifies the glycosidic linkage between unsulfated GlcA and GlcNS3S6S. This conformational change is propagated to the remaining three sugar residues in the pentasaccharide. The N-sulfate, 2-O-sulfate and 6-O-sulfate are alternately arranged on each side of the AGA*IA pentasaccharide ( Figure 10A ) or the N-sulfated heparin structure, while glycol-splitting introduces a "kink" and generates novel structures where the O-sulfate groups of adjacent disaccharide units reside on the same side of the GAG chain and are involved in the binding to the enzyme ( Figure 10B ). These binding modes are in agreement with the previously proposed hypothesis of binding of the glycol-split oligosaccharides to the active site of heparanase ).
PI-88 (compound 12) is a mixture of highly sulfated oligosaccharides, ranging from disaccharides to hexasaccharides, with the majority (60%) being pentasaccharides, and inhibits angiogenesis and metastasis by virtue of its inhibition of heparanase (Yu et al. 2002) . Furthermore, structure-activity relationship studies have indicated that tetrasaccharides exhibit comparable activity to that of pentasaccharides in cell-based and ex vivo assays of angiogenesis (Johnstone et al. 2010 ). The binding modes of pentasaccharides of PI-88 (compound 12) and its analog (compound 13, which is hydrophobic aromatic in nature) were investigated. Docking of PI-88 and compound 13 indicates that the pentasaccharide is able to bridge HBD-1 and HBD-2. The docked poses can be clustered into two binding modes. In the majority of binding modes, the sulfates from both molecules make electrostatic interactions with the side chains of Lys159, Lys161 and Arg272, whereas hydrogen bonds were made with the side chains of Gln270, Tyr298 and Ser228. No interactions were observed with the phosphate group of PI-88. The representative docked poses of compound 13 from both the clusters are shown in Supplementary data, Figure S3 . The CH 2 -Ph group fits in the hydrophobic pocket formed by Ala352 and neighboring residues Gly350 and Pro353. On the other hand, in the second cluster, the CH 2 -Ph ring is oriented toward Phe229. Docking simulations cannot reliably rank this class of ligands as the differences in the predicted binding affinities of PI-88 analogs are not very large (Johnstone et al. 2010) . Hence a representative ligand (compound 13) was used to predict the binding mode of similar classes of compounds.
Unlike α-L-iduronic acid, which may have proton donor Glu225 is within the hydrogen-bonding distance of the glycosidic bond oxygen and the residue Glu343 is within the contact distance to facilitate the nucleophilic attack on the anomeric carbon in subsite −1. Based on the docking of substrates and inhibitors, the structural features of the active site of heparanase are proposed in Supplementary data, Figure S4 . Besides catalytic residues, which act as proton donors and acceptors, and the heparin-binding domains, which consist of basic residues, the active site has a hydrophobic/aromatic patch formed by residues Phe129 and Leu230, and another similar patch formed by residues Phe160, Ala347, Ala352, Val384 and Ala388. Various hydrophobic groups could target these hydrophobic regions in the rational design of heparanase inhibitors. The docking of substrates and inhibitors indicates the presence of a large binding site extending over at least two saccharide units beyond the cleavage site (toward the nonreducing end) and at least three saccharides toward the reducing end (toward HBD-2).
In the work reported in this paper, the interglycosidic torsion angles of disaccharide substrates bound to heparanase were measured and compared with the corresponding torsion angles determined from experimental NMR and X-ray crystallographic determinations as well as MD simulations (Supplementary data, Table S4 ). The φ angles for molecules 2, 3 and 6 and the ψ angles for substrate 6 are inconsistent with the data from related structures, suggesting that AutoDock has a marked tendency to distort interglycosidic torsion angles away from normally expected values. MD simulations of free molecules such as cellulose, chitin, mannan, xylan and hyaluronan, in the presence of an explicit solvent have been used to correct the glycosidic torsions around β(1 → 4) (Almond and Sheehan 2003) , which is the linkage found in most of the hexapyranoses studied here. However, MD simulations with unrestrained β-D-glucuronic acid demonstrated that the force fields are unable to reproduce the experimentally observed prevalence of the 4 C 1 chair conformation (Sattelle and Almond 2010) . In such a scenario, it seems appropriate to select docked poses on the basis of favorable torsion angles in a cluster (Table IV and  Supplementary data, Table S4 ) at the expense of those with the best free energies (and the rank of the cluster). As seen from experimental data for GlcA oligosaccharides (Supplementary data, Table S4), the glycosidic torsions vary with the chain length. Furthermore, sulfation on glucosamine can change the torsion angles of the disaccharides. Therefore, the conformations of molecules 2 and 3 are reasonable. The docked poses of substrates 6 and 7 do not follow the expected conformational preferences and hence the predicted interactions of these molecules should not be taken into consideration for rational drug design.
The docking results reported here also suggest the presence of an induced-fit mechanism in the binding of substrates to the catalytic and HBDs of heparanase. The existence of such induced fit in the enzyme has been proposed in cel5 endoglucanase (PDB code 1CEN) from C. thermocellum (Dominguez et al. 1996) and family 51 arabinofuranosidase (PDB codes 2VRQ and 2VRK) from Thermobacillus xylanilyticus (Paes et al. 2008) . Furthermore, the catalytic site consisting of the 224NEP226 motif is a loop which might impart some flexibility and impact substrate binding. In addition, increased flexibility is conferred near the HBD-1 domain by cleavage of the interchain disulfide bond Cys127-Cys179.
The His residue forms part of the catalytic triad in clan A family, while the second residue is a strictly conserved Glu ( proton donor), but variations (either Ser, Thr, Glu, Asp or water) are observed in the third residue of the triad (Debeche et al. 2002; Nielsen and McCammon 2003b) . The H296XY298 sequence (where X is any residue) in heparanases is also present in endoglucanases or cellulose-binding proteins and in α-L-arabinofuranosidases and xylanases, but structural superimposition with various clan A members did not reveal the presence of any conserved or semiconserved residues that can form a triad in heparanase. Furthermore, docking simulations with substrates and analyses with FINDSITE with various ligands indicate that Tyr298 is involved in direct interactions with the substrates, whereas His296, although conserved, is not involved in any direct hydrogen bonding with the substrate. There are Ser, Thr, Asp and Glu residues in the vicinity of the catalytic binding site but at a distance not sufficient to form hydrogen bonds with the His or Glu residues of the classic triad. Therefore, the Glu225-His296 dyad is suitably positioned to lower the pK a of the acid/base residue and has a common catalytic mechanism that involves two conserved acidic residues, a putative proton donor at Glu225 and a nucleophile at Glu343.
Previous molecular modeling studies have identified residues Lys139, Val170, Asp171, Thr175, Arg307, Trp 340 and Tyr264 as important for the binding of small-molecule inhibitors of heparanase (Zhou et al. 2006) . However, no mutagenesis data is available to validate these predictions. No interactions of these residues with carbohydrate-based ligands were observed in this docking study. NMR and surface plasmon resonance methods identified residues Glu225, Glu343, Lys158, Lys161, Arg272 and Thr275 as important for the binding of polysulfonated ligands such as suramin (Mosulen et al. 2011) . Molecular modeling studies found Phe229 in the binding site to be also important for activity of KI-105 ). The docking simulations reported here agree with the experimental observations Mosulen et al. 2011) .
Conclusions
Homology modeling together with the Conseq and FINDSITE analyses lends insights into the structure-function relationships of heparanase. In contrast to the apparent structural similarities between families 5, 10, 30, 39 and 51 and heparanase, structural links between the substrate-binding clefts of family 44 and endoglucuronidase were established. The binding of β-glucopyranoside substrates to glycosyl hydrolase 79 heparanase has been investigated using ligand-protein docking simulations to increase our understanding of substrate specificity of heparanase, wherein the substrate includes a GlcA and a GlcNS unit carrying O-sulfation. Molecular docking and pK a prediction calculations show that Glu225 acts as the proton donor in human heparanase and that the enzyme is an antiprotonator. The distance between Glu225 and the glycosidic linkage of the substrate may determine the specificity Molecular modeling of the interactions of heparanase and oligosaccharides according to the substrate docking model. We have proposed substrate recognition sites on heparanase based on docking studies. Various GAG-based inhibitors were docked to determine which amino acids in the protein interact with these sulfated sugar molecules. Apart from electrostatic interactions with the heparin-binding domains, hydrophobic interactions also contribute to the increase in binding affinity of several GAG-based inhibitors. Several interactions of ligands such as PI-88 analogs, which contain hydrophobic linkers, can be observed in the active site formed by residues Phe129 and Leu230. Consequently, future mutagenesis studies on residues 227-230 in the catalytic active site will aid the rational design of heparanase inhibitors. These docking ligand-protein complex models can interpret the substrate specificity of heparanase, providing a rationale for the design of polysaccharides (e.g. IdoA2S at subsite −1) that may act as inhibitors of the enzymatic activity of heparanase. Predicted heparin/enzyme complexes show that the interactions of the heparin-binding domains in combination with the catalytic domain can be targeted for the design of inhibitors. These findings also emphasize the challenges in the use of molecular modeling methods for the development of new inhibitory nonanticoagulant molecules against the enzymatic functions of heparanase.
Materials and methods
ConSeq analysis
Given a sequence and an alignment of homologous sequences, the ConSeq (Berezin et al. 2004 ) server maps functionally important residues that take part in ligandbinding and protein-protein interactions onto each amino acid in the primary sequence. ConSeq takes into account the evolutionary conservation and solvent accessibility profiles to indicate residues that have potential structural or functional importance. A PSI-BLAST (Altschul et al. 1997 ) search was performed against the CLEAN_UNIPROT (filtered UNIPROT database in Consurf ) (Goldenberg et al. 2009 ) to search for nonredundant homologs. The query sequences correspond to the heparanase human sequence (Q9Y251). To map evolutionary conservation scores onto the query sequence, a multiple sequence alignment (MSA) from clan A hydrolases (Supplementary data, Table S1 ) was calculated using the MAFFT (Katoh and Toh 2008) alignment algorithm implemented in the new ConSurf server (Ashkenazy et al. 2010) . The sequences, species, SWISS-PROT (Boeckmann et al. 2003 ) accession numbers and sequence identity with reference to human heparanase are listed in Table II and  Table S1 .
The Rate4Site algorithm (Pupko et al. 2002) was subsequently used to construct a phylogenetic tree using the neighbor-joining algorithm and to calculate evolutionary conservation scores. An empirical Bayesian approach was used to calculate the evolutionary rate of each amino acid position of the MSA, taking into account the stochastic nature of the evolutionary process. Amino acid evolution is traced using the JTT substitution model (Jones et al. 1992) . The conservation codes were projected onto the heparanase sequence and MSA, and color-coded, where 1 corresponds to maximal variability and 9 to maximal conservation. The phylogenetic tree produced by ConSeq was plotted using FigTree 1.2.2 (Rambaut 2006b ).
Homology modeling
The secondary structure was predicted using PSIPRED. The secondary structure consensus prediction program (NPSAnetwork protein sequence analysis) (Combet et al. 2000) , which combines the DSC (Discrimination of protein Secondary structure Class) (King and Sternberg 1996) , MLRC (Guermeur et al. 1999) , PHD (Profile network from HeiDelberg) Sander 1993, 1994) and Predator (Frishman and Argos 1996) methods, was used to generate a secondary structure consensus and validate the prediction. As stated earlier, heparanase consists of 543 amino acids that can be structured into three domains, encompassing the 157 N-terminal regions, the catalytic domain and a C-terminal domain Val418-Ile543. The N-terminal domain is crucial for expression and activity (Hulett et al. 1999) , while the hydrophobic C-terminal domain, consisting of disulfide bridge Cys437-Cys542, is critical for heparanase activity and secretion (Simizu et al. 2007) , as well as for mediating nonenzymatic functions of heparanase, facilitating Akt phosphorylation, cell proliferation and tumor xenograft progression (Lai et al. 2008; Fux, Feibish, et al. 2009 ). Recently, the region encompassing residues 158-417, which includes the GAG-binding site, was found suitable for drug-discovery purposes in the search for novel inhibitors of heparanase (Mosulen et al. 2011) . We focused on regions from 158 to 543 for the purpose of binding site refinement and docking studies.
Structure construction, assignment of disulfide bridges, optimization and visualization were performed using the molecular modeling package Discovery Studio 2.5 (Accelrys, Inc.). Ten models were constructed and loops were built using the discrete optimized protein energy (Shen and Sali 2006) loop-modeling protocol in MODELLER (Sali and Blundell 1993) . Essential hydrogen and charges were added to the structure. After coarse energy minimization, the model with the lowest PDF energy was assessed for its overall geometric and stereochemical quality using the Ramachandran plot and the Verify3D server (Bowie et al. 1991; Luthy et al. 1992) .
At a physiological pH or above, heparanase is inactive, does not cleave HS but binds it to the ECM or cell-surface HSPGs, thereby facilitating inflammatory leukocyte adhesion (Gilat et al. 1995; Ihrcke et al. 1998) . Heparanase is active in the pH range 4.0-7.5, with maximal activity between pH 5.5 and 5.8 (Gilat et al. 1995; Graham and Underwood 1996; Freeman and Parish 1998) , cleaving HSPGs. Consequently, all ionizable residues were protonated depending on their pK a using the H++ (Gordon et al. 2005) web server, based on finite difference Poisson-Boltzmann calculations and PropKa 3.0 (Olsson et al. 2011) . The model from PropKa was further evaluated for flexibility by MD simulations, while the reliability of the model was evaluated by docking and binding analyses.
Electrostatic potential surface calculations
Electrostatic potential surface calculations were done using the DelPhi program (Sharp et al. 1998 ) implemented in DS NS Gandhi et al. Modelling 2.1 (Accelrys, Inc.) using the default Delphi atomic partial charges and radii, with a protein interior dielectric constant of 1, a solvent dielectric constant of 80 and an ionic strength of 0.145 M.
MD simulations
All energy minimizations and MD simulations were performed with AMBER 9.0 (Case et al. 2005) . The Parm99SB (Viktor et al. 2006) force field in AMBER 9.0 was used for the simulations of heparanase. A cubic box of TIP3P water molecules (Jorgensen et al. 1983 ) was added to solvate the protein, keeping a minimum distance of 12.0 Å between each face of the box and the protein. The number of water molecules added to the heparanase structure was 19 632. Net charges in the protein were neutralized by adding an appropriate number of chloride ions.
In each simulation, initial unfavorable contacts with the solvent were removed by energy minimization after performing 10 steps of steepest descents followed by 990 steps of conjugate gradients, keeping the protein rigid. The system was energy-minimized again as before, allowing the side chains and then the entire structure to relax. A force constant of 25 kcal/mol Å 2 was used to restrain the atoms of the system that were not being relaxed. Three stages of MD equilibration were performed to relax water and hydrogen atoms (200 ps), side chains (200 ps) and the whole system (500 ps). Finally, a 1.0 ns production simulation was performed. A timestep of 2.0 fs was used in all simulations and the coordinates were saved every 10 ps. During all simulations, the particle mesh Ewald method (Tom et al. 1993 ) was used to compute long-range electrostatic interactions, using a 1.0 Å grid spacing and a fourth-order spline for interpolation. The nonbonded cutoff was set to 10.0 Å and the SHAKE algorithm (Ryckaert et al. 1977) was used to constrain all bonds involving hydrogen atoms. All simulations were carried out in the isobaric-isothermal ensemble at a pressure of 1 atm. The temperature and pressure were kept constant using the weak-coupling algorithm with coupling constants τ T and τ P of 0.1 and 1 ps, respectively (Berendsen barostat) (Berendsen et al. 1984) . Periodic boundary conditions were applied throughout.
Binding site prediction Ligand-binding residues were identified in the target structure using FINDSITE (Brylinski and Skolnick 2008 , 2009 Skolnick and Brylinski 2009 ), a structure/evolution-based method for ligand-binding site prediction and molecular function inference. FINDSITE detects common ligand-binding sites in a set of evolutionarily related proteins with <35% sequence identity to the target. As the targets for local refinement, we used the best of top five binding sites predicted within 6 Å from the geometrical centre of a bound ligand in the reference crystal structure. FINDSITE also provides information on the chemical identity of molecules that likely occupy the predicted binding sites by performing virtual screening against the ZINC, NCI and other databases. This feature was not used in our work.
Molecular docking
The structures of substrates and inhibitors used in this work are listed in Table II . The backbone of each molecule was constructed using the building facility offered at the GLYCAM web server (Woods 2005 (Woods -2011 , which provides the final coordinates in PDB format. The coordinates of the AGA*IA pentasaccharide were taken from the X-ray structure of the complex of antithrombin and Factor Xa (PDB code 2GD4) (Johnson et al. 2006) . Structural modifications were carried out using Discovery Studio 3.0 (Accelrys, Inc.). Coombe et al. (2008) , Gandhi and Mancera (2011) and others have shown that AutoDock can be used to perform docking of carbohydrates to their protein targets, and the scoring function can reasonably rank the relative binding affinities of carbohydrate ligands/substrates (Coutinho et al. 1997 (Coutinho et al. , 1998 Bitomsky and Wade 1999; Mulakala and Reilly 2002; Mertz et al. 2007; Takaoka et al. 2007; Cantu et al. 2008; Coombe et al. 2008; Gandhi et al. 2008; Hill and Reilly 2008) , although much more expensive MD approaches have been used successfully for relatively small GAG fragments (Gandhi and Mancera 2009) . The drawback of AutoDock is the need to reach a compromise between accuracy and efficiency. In particular, the number of energy evaluations for each run had to be set to allow some runs to produce docked conformers in a reasonable amount of computer time. This issue becomes especially critical with an increasing number of torsions in the ligand molecule (over 18 for a trisaccharide), since the additional torsions add several more degrees of freedom in the system. Hence, in this work we used two different approaches for docking ligands with at least 12 rotatable bonds. The molecular docking engine FRED (2008a) was first used to dock ligands in the active site followed by redocking and scoring of the poses with the Lamarckian genetic algorithm (LGA) (Morris et al. 1998 ) method in Autodock 4.2 (Morris et al. 2009 ). During both stages, the ligand was allowed full flexibility, whereas the protein was held rigid. While most of the docking programs can accommodate flexibility in the protein, this was not practical in our study as there are too many flexible basic residues in the binding site that interact with flexible ligands, such as GAGs. Furthermore, molecules such as heparin have a large number of torsional degrees of freedom, which can lead to the failure of the search method to find binding poses effectively.
The program OMEGA v.2.3.2 (FRED 2008b) was used to convert all molecules described into 3D multiconformer structures and to add hydrogen atoms and partial charges using the MMFF force field (Thomas 1996a (Thomas , 1996b (Thomas , 1996c Thomas and Robert 1996) . The maximum number of conformers (maxconfs) was set to 50. OMEGA was used because of its ability to enumerate ring conformations and invertible nitrogen atoms. This method is useful in enumerating ring conformations in heparin, particularly sulfated α-L-iduronate (IdoA2S) residues, which may adopt skewboat ( 2 S 0 ) and chair ( 1 C 4 ) conformations (Ferro et al. 1990 ). The multiconformer database of one or more ligands generated by OMEGA was used as input to the molecular docking engine FRED (2008a) . The active site of the protein was defined on the basis of the superimposed ligands predicted by FINDSITE, as described in the section Molecular modeling of the interactions of heparanase and oligosaccharides on binding site prediction. The "inner contour" (a shape complementary to the active site, used during the exhaustive search) was disabled as the substrate-binding sites of endohydrolases consist of clefts or sets of juxtaposed surface residues rather than pockets (Esko and Linhardt 2009) . Distance constraints between the catalytic residues and the GlcA substrate were setup using the FRED receptor module. The number of poses (num_poses) to be returned by the exhaustive search was set to 5000, defined as the top scoring poses selected from the list of all poses and scored by the scoring functions specified by the exhaustive scoring. The number of alternative poses (num_alt_poses) was set to 300, defined as additional poses to the top consensus structure poses. In the optimization step, four scoring functions were used: ChemGauss, ChemScore (Eldridge et al. 1997) , PLP (Gehlhaar et al. 1995) and ScreenScore (Stahl and Rarey 2001) . Binding poses obtained from FRED using the consensus score were extracted and submitted for redocking.
For redocking, the global minimum structure and the lowenergy structures of the significant representative conformations of a given oligosaccharide were subjected to docking, but using the LGA in AutoDock with a population of 200 individuals, 256 runs and 50 × 10 6 energy evaluations, and permitting a maximal translation of 0.1 Å per step, followed again by the cluster analysis. To reduce the number of degrees of freedom, the pyranosyl ring at subsite −1 was fixed but full flexibility of all rotatable dihedral angles was allowed. In all simulations, the mutation rate was set to 0.80, the crossover rate was 0.02, the maximal number of generations was 2.7 × 10 4 , elitism was set to 1 and the local search frequency was 0.06. The grid box was defined with a constant grid spacing of 0.37 Å around each ligand molecule using the previously obtained binding pose. The AutoDock 4.0 scoring function (Huey et al. 2007 ) was used to predict the free energies of ligands shorter than tetrasaccharides.
Most of the modeling studies (docking or MD simulations) described to date have been carried out using crystal structures of glycosyl hydrolases in complex with nonsulfated monosaccharide, disaccharide or trisaccharide substrates (Coutinho et al. 1997; Mulakala and Reilly 2002; Mertz et al. 2007 ). The molecular mechanics-based scoring functions fail to predict binding affinities for molecules such as heparin with a large number of degrees of freedom (translational, rotational and torsional). Hence, AutoDock scoring was not carried out for molecules bigger than a trisaccharide.
Visualization
All the 3D protein and ligand structures were edited and visualized using Discovery Studio 3.0 (Accelrys, Inc.). Consurf results and MD simulation trajectories were visualized using UCSF Chimera (Eric et al. 2004 ).
Supplementary data
Supplementary data for this article is available online at http:// glycob.oxfordjournals.org/. 
